MARKET

ADIL

ADIL

Adial Pharmaceuticals Inc
NASDAQ
2.800
+0.010
+0.36%
After Hours: 2.780 -0.02 -0.71% 19:55 07/17 EDT
OPEN
2.860
PREV CLOSE
2.790
HIGH
2.902
LOW
2.700
VOLUME
36.44K
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
1.310
MARKET CAP
6.13M
P/E (TTM)
-0.2819
1D
5D
1M
3M
1Y
5Y
1D
Coastlands Capital LP reports $8,689 Adial Pharmaceuticals common share purchase
PUBT · 2d ago
Coastlands Capital LP reports Adial Pharmaceuticals common share purchase worth $32,613.87
PUBT · 5d ago
Weekly Report: what happened at ADIL last week (0706-0710)?
Weekly Report · 6d ago
Weekly Report: what happened at ADIL last week (0629-0703)?
Weekly Report · 07/06 10:21
Major Investor Quietly Boosts Stake in Adial Pharmaceuticals
TipRanks · 07/02 02:04
Coastlands Capital LP buys 25,000 Adial Pharma shares worth $65,000
PUBT · 07/01 14:31
Adial Pharmaceuticals initial beneficial ownership filing lists Coastlands Capital LP as 10% owner
PUBT · 06/29 16:48
Weekly Report: what happened at ADIL last week (0622-0626)?
Weekly Report · 06/29 10:16
More
About ADIL
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.

Webull offers Adial Pharmaceuticals Inc stock information, including NASDAQ: ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.